跳轉至內容
Merck
全部照片(1)

重要文件

L0400000

左多巴

European Pharmacopoeia (EP) Reference Standard

同義詞:

左旋多巴, 3-(3,4-二羟基苯基)-L-丙氨酸, 3-羟基-L-酪氨酸, L-DOPA, 左多巴

登入查看組織和合約定價


About This Item

線性公式:
(HO)2C6H3CH2CH(NH2)CO2H
CAS號碼:
分子量::
197.19
Beilstein:
2215169
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

levodopa

製造商/商標名

EDQM

mp

276-278 °C (lit.)

應用

pharmaceutical (small molecule)

形式

neat

儲存溫度

2-8°C

SMILES 字串

N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O

InChI

1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1

InChI 密鑰

WTDRDQBEARUVNC-LURJTMIESA-N

基因資訊

human ... DRD3(1814)

尋找類似的產品? 前往 產品比較指南

一般說明

本品按现行药典规定交付。所有为支持本产品而提供的信息,包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持,请访问现行药典网站。

應用

左旋多巴EP参考标准品的预期用途是欧洲药典规定的实验室测试。

包裝

本品按照现行药典要求提供。有关当前单位数量,请见EDQM 参考目录

其他說明

可能适用相应的销售限制。

象形圖

Exclamation mark

訊號詞

Warning

危險分類

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Damian M Herz et al.
Annals of neurology, 75(6), 829-836 (2014-06-04)
In Parkinson disease (PD), long-term treatment with the dopamine precursor levodopa gradually induces involuntary "dyskinesia" movements. The neural mechanisms underlying the emergence of levodopa-induced dyskinesias in vivo are still poorly understood. Here, we applied functional magnetic resonance imaging (fMRI) to
Pol Nadal-Jimenez et al.
Journal of bacteriology, 196(14), 2681-2690 (2014-05-13)
The iron binding siderophore pyoverdine constitutes a major adaptive factor contributing to both virulence and survival in fluorescent pseudomonads. For decades, pyoverdine production has allowed the identification and classification of fluorescent and nonfluorescent pseudomonads. Here, we demonstrate that PvdP, a
Nicolas Morin et al.
Experimental neurology, 256, 105-116 (2013-01-31)
The treatment of motor symptoms of Parkinson disease (PD) with the dopamine (DA) precursor, l-3,4-dihydroxyphenylalanine (l-DOPA) introduced 50years ago still remains a very effective medication. However, involuntary movements termed l-DOPA-induced dyskinesias (LID) appear in the vast majority of PD patients
Lukas L Imbach et al.
Parkinsonism & related disorders, 20(11), 1283-1286 (2014-09-28)
Diagnosis and treatment of tremor are largely based on clinical assessment. Whereas in some patients tremor may respond to dopaminergic treatment, in general l-Dopa response to tremor varies considerably. The aim of this study was to predict l-Dopa response by
Vincent J J Odekerken et al.
Neurology, 84(13), 1355-1361 (2015-03-01)
To assess the neuropsychological outcome 12 months after bilateral deep brain stimulation (DBS) of the globus pallidus pars interna (GPi) or subthalamic nucleus (STN) for advanced Parkinson disease. We randomly assigned patients to receive either GPi DBS or STN DBS.

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務